Stockscreener 앱 받기
2.99
0.33%
-0.010
시간 외 거래:
2.99
Allogene Therapeutics Inc 주식(ALLO)의 최신 뉴스
Allogene Therapeutics to Present New Data Demonstrating the - GlobeNewswire
Allogene Therapeutics to Present New Data Demonstrating the Potential of Allo-316 in Heavily Pretreated Adult Patients with Cd70 Positive Advanced Renal Cell Carcinoma At the International Kidney Cancer Symposium and Society for Immunotherapy of Ca - Marketscreener.com
Allogene Therapeutics (NASDAQ:ALLO) Stock Price Up 6.3%Still a Buy? - MarketBeat
Palisade Bio (NASDAQ:PALI) and Allogene Therapeutics (NASDAQ:ALLO) Critical Survey - Defense World
Allogene Therapeutics Announces Participation in November Investor Conferences - StockTitan
Allogene Therapeutics’ (ALLO) “Buy” Rating Reiterated at HC Wainwright - Defense World
Will Allogene Therapeutics (ALLO) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance
Allogene Therapeutics (ALLO) Scheduled to Post Quarterly Earnings on Thursday - MarketBeat
Allogene shares hold buy rating as FDA grants RMAT to ALLO-316 - Investing.com Australia
HC Wainwright Reiterates "Buy" Rating for Allogene Therapeutics (NASDAQ:ALLO) - MarketBeat
Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update - GlobeNewswire
FDA grants RMAT status to Allogene's kidney cancer therapy By Investing.com - Investing.com South Africa
FDA grants RMAT status to Allogene's kidney cancer therapy - Investing.com
We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully - Yahoo Finance
Allogene Therapeutics Receives FDA Regenerative Medicine - GlobeNewswire
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Allogene Therapeutics (NASDAQ:ALLO) Stock Price Up 6.6%Time to Buy? - MarketBeat
Allogene Therapeutics Inc (NASDAQ: ALLO) Stock Forecast: Could Pass $55 In A Year - Stocks Register
Allogene Therapeutics (NASDAQ:ALLO) Shares Down 5.4%Should You Sell? - MarketBeat
Research Analysts Offer Predictions for ALLO Q3 Earnings - MarketBeat
Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Exchange Traded Concepts LLC Acquires 12,328 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) - Defense World
AQR Capital Management LLC Purchases Shares of 27,287 Allogene Therapeutics, Inc. (NASDAQ:ALLO) - Defense World
Allogene Therapeutics (ALLO) Stock Surges Amid Biotechnology Sec - GuruFocus.com
Wall Street analysts’ outlook for Allogene Therapeutics Inc (ALLO) - SETE News
Allogene Therapeutics Inc [ALLO] Investment Guide: What You Need to Know - Knox Daily
Allogene Therapeutics Inc’s Market Journey: Closing Strong at 2.65, Up 1.15 - The Dwinnex
The Allogene Therapeutics Inc (ALLO) had a good session last reading, didn’t it? - US Post News
The Manufacturers Life Insurance Company Has $1.12 Million Stock Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat
126,628 Shares in Allogene Therapeutics, Inc. (NASDAQ:ALLO) Purchased by Squarepoint Ops LLC - Defense World
Taking a look at what insiders are doing to gauge the Allogene Therapeutics Inc (ALLO)’s direction - Knox Daily
Ready to Jump After Recent Trade: Allogene Therapeutics Inc (ALLO) - SETE News
Allogene Therapeutics Inc (ALLO) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
Dimensional Fund Advisors LP Increases Stock Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat
Allogene Therapeutics (ALLO) Sees 5% Stock Surge Amidst Biotech Sector Movement - GuruFocus.com
Allogene Therapeutics Inc’s Market Journey: Closing Strong at 2.70, Up 3.45 - The Dwinnex
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Allogene Therapeutics Inc (ALLO) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Allogene Therapeutics, Inc. (ALLO): Among the Rising Penny Stocks to Invest In Now - Insider Monkey
Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Act - GuruFocus.com
Market Insights: Allogene Therapeutics Inc (ALLO)’s Notable Drop of -4.64, Closing at 2.67 - The Dwinnex
You might want to take a look at Allogene Therapeutics Inc (ALLO) now - SETE News
Allogene Therapeutics (NASDAQ:ALLO) Trading Down 6.4% - MarketBeat
7 Best Rising Penny Stocks To Invest In Now - Insider Monkey
Allogene Therapeutics (ALLO) Shares Dip 5.15% Amid Market Volati - GuruFocus.com
Understanding the Risks of Investing in Allogene Therapeutics Inc (ALLO) - Knox Daily
Did Allogene Therapeutics Inc (ALLO) perform well in the last session? - US Post News
Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference - GlobeNewswire
Perceptive Advisors LLC Takes Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Shares Bought by Renaissance Technologies LLC - MarketBeat
Wall Street SWOT: Allogene stock navigates expanded rights and clinical milestones - Investing.com
Allogene Therapeutics (ALLO) Stock Jumps by 5.15% - GuruFocus.com
Wall Street SWOT: Allogene stock navigates expanded rights and clinical milestones By Investing.com - Investing.com South Africa
Lynx1 Capital Management LP Invests $5.19 Million in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat
Allogene reveals next-gen CAR T candidate for autoimmune disease - Investing.com India
Allogene reveals next-gen CAR T candidate for autoimmune disease By Investing.com - Investing.com Canada
Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence - GlobeNewswire
Allogene Therapeutics to Present Pre-Clinical Data - GlobeNewswire
A better buy-in window may exist right now for Allogene Therapeutics Inc (ALLO) - SETE News
2.02%
0.47%
자본화:
|
볼륨(24시간):